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GSC G144 G179 Dr. Peter Dirks Arthur and Sonia Labatt Brain 
Tumor Research Center, Toronto, Canada Pollard et al., 
2009 GSC sphere
GSC Y10 80  Y02 70  Y04
63 Y14 71
Sadahiro et al., 2014 GSC
trypsin 1.33 
mg/mL hyaluronidase 0.67 mg/mL  kynurenic acid 0.17 mg/mL 37°C
50 EGF 20 
ng/mL FGF 20 ng/mL neurosphere
accutase neurosphere 1% laminin 37  overnight
dish Hormone mix EGF 20 ng/mL FGF
20 ng/mL B27 Carlsbad CA USA 3 4
accutase 1:5 1:8
Dulbecco’s modified Eagle’s medium DMEM
10 FBS 9 21 B27 Invitrogen 
Carlsbad, CA, USA FBS HyClone Laboratories, Inc. Logan, UT, USA
Sigma-Aldrich Corporation St. Louis, MO, USA
4-3. De novo
De novo [14C]-glucose PerkinElmer, Boston, MA, USA
[14C]-acetate PerkinElmer
FBS
[14C]-glucose  [14C]-acetate 24 8
PBS
bicinchoninic acid Pierce, Rockfold, IL, USA
Bligh-dyer Bligh et al., 1959
0.5 ml 0.25 ml 2
20 0.2 ml
0.2 ml PBS voltex 3000 rpm 20
/
19:1 5 ml Ultima gold liquid scintillation counting 
cocktail PerkinElmer Aloka 
radioisotope counter machine DPM/ g protein
4-4. PCR
RNeasy plus Mini kit Qiagen total RNA
total RNA
Promega NANODROP LITE Thermo Scientific, Hudson, NH, USA
mRNA Transcriptor High Fidelity reverse transcriptase 
kit Roche Diagnostics, GmbH, Mannheim Germany oligo d T
cDNA
PCR qPCR Applied Biosystems StepOnePlusTM real-time PCR 
system Applied Biosystems, Carlsbad, CA, USA Taqman® 
Applied Biosystems nestin Hs04187831_g1 CD133 prominin1
Hs01009250_m1 Sox2 Hs00415716_m1 FABP7 Hs00361426_m1 18SmRNA
Hs03928985_g1 18SmRNA Ct Ct
Ct Ct
Ct Applied Biosystems StepOnePlusTM real-time PCR system 
software v2.0 Applied Biosystems
4-5. NOD-SCID mouse
NOD-SCID 5 20 25 g NOD/SCID 
30G
1 100,000 PBS2 l Bregma
1 mm 2 mm 2.5 mm 2
5
22
FASN Sigma-Aldrich, 1:100 1
rabbit IgG Vector Laboratories, Burlingame, CA, 
USA, 1:200 2
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HISTOFINE pH 9
Microwave 40 Protein 
block Protein Block Serum-Free Ready-To-Use Dako 10
rabbit anti-FASN antibody Sigma-Aldrich, 1:100 60
alkaline phosphatase-conjugated donkey anti-rabbit IgG Jackson 
ImmunoResearch Laboratories West Grove PA USA 1:50 30
Vulcan Fast Red Chromogen Kit 2 BIOCARE MEDICAL
Concord CA USA FABP7
alkaline phosphatase ALP
denaturing solution kit BIOCARE MEDICAL 5
ALP goat anti-Sox2 antibody Santa Cruz 
Biotechnology Dallas Texas USA 1:100 60
ALP-conjugated donkey anti-goat IgG Jackson ImmunoResearch 
Laboratories 1:50 30 PermaBlue/AP
Diagnostic BioSystems Pleasanton CA USA Sox2
4% 
15
5% 40 rabbit 
anti-FASN 1:100  mouse anti-nestin Millipore Corporation Billerica, MA, USA, 
1:200 goat anti-Sox2 1:500 antibody or mouse anti-CD133 Miltenyi Biotec Inc., 
Auburn, CA, USA, 1:50 4°C Alexa Fluor® 
488 goat anti-rabbit IgG, Alexa Fluor® 488 goat anti-mouse IgG, Alexa Fluor® 568 
goat anti-rabbit IgG, or Alexa Fluor® 568 donkey anti-goat IgG Invitrogen, 0.5 g/ml
1 4', 6-Diamidino-2- phenylindole
DAPI Sigma-Aldrich MO USA Fluoromount Diagnostic 
BioSystems CA USA LSM710, Carl Zeiss, 
Oberkochen, Germany ImageJ
4-7. 
100 mM Tris-Cl pH 6.8 4% SDS 20% glycerol 200 mM -mercaptoethanol
buffer BCA Protein 
assay Pierce Rockfold IL USA 15–30 µg
12%SDS-polyacrylamide SDS-PAGE
Immobilon-PSQ polyvinylidene difluoride membrane Millipore, USA 5% 
skimmed milk anti-FASN Sigma-Aldrich, 
1:1000 anti-CD133 Miltenyi Biotec, 1:100 anti-FABP7 Owada et al., 2006, 
1:1000 anti-nestin Millipore, 1:5000 anti-Sox2 Millipore-Chemicon 1:1000
anti- -actin Santa Cruz Biotechnology, 1:2000 4
HRP 2 Millipore MA USA 1
ECL reagents GE Healthcare UK Ltd, Amersham Place, England
4-8. 
Cerulenin GSCs MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3- 
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt]
MTS CellTiter 96 Aqueous nonradioactive cell proliferation 
assay kit Promega, Madison, WI, USA
96 8,000
cerulenin 0 24 48 72 MTS MTS
2.5 490 nm ARVOTM X Multilabel Plate Reader 
PerkinElmer
4-9. 
GSCs Matrigel BD Bioscience, San Jose, CA, USA
8 m Transwell inserts Corning Life Sciences, Corning, NY, 
USA 200 g/ml Matrigel
DMEM/F-12 FGF EGF DMEM/F-12 FGF
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55-1. GSCs de novo
de novo Brown et al., 2007
GSCs dif-GSCs de novo
DMEM-F12 14[C]-glucose
GSCs G144 Y10 G179 65.38 ± 4.45 DPM/ g
48.16 ± 3.76 DPM/ g 86.52 ± 11.30 DPM/ g
dif-G144 dif-Y10 dif-G179 32.32 ± 0.82 DPM/ g
12.38 ± 0.48 DPM/ g 34.09 ± 1.38 DPM/ g GSCs de novo
Fig. 1A 14[C]-acetate G144 Y10 G179
271.73 ± 18.26 DPM/ g 235.82 ± 30.84 DPM/ g 323.07 ± 29.91 DPM/ g
dif-G144 dif-Y10 dif-G179 99.62 ± 0.98 DPM/ g 52.86 
± 5.33 DPM/ g 110.08 ± 29.65 DPM/ g Fig. 1B
dif-GSCs GSCs de novo
Fig. 1.
differentiated non
G144, Y10 and G179 cells were incubated with 
for 24 






2013; Berezovsky et al., 2014
De novo
or 8 h to measure glucose or acetate incorporation 



























rce in GSCs and 














neural stem cell marker, Sox2
FASN




 in the 
Sox2
 in human glioblastoma 
cells show the strong expression of FA
 (red). Sox2 expression is confined to the nuclei, 
















Western blotting showing the expression of 
Y10, G179, Y02, Y04 and Y14
FASN
Expression of 
lines before and after differentiation.
neural stem cell markers, Sox2
of FB
Immunofluorescence micrographs showing the 
a’) and nestin (
showing the morphology of GSC lines (G144
(d, h) or after differentiation in the presence of F
Bars in 
Fig.





S, FASN expression is down
d, h, d’ =
3. Downregulation of FASN mRNA expression upon differe
Upon differentiation in the 




b, f, b’) in G144
20 µm 
strong expression of FA
FABP7, 
GSC lines. Upon d
to that of CD133, 


















ifferentiation in the presence of F
, and FABP7, was
(C) Expression of FA
rong expression of FA
. Upon differentiation in the presence 
to that of Sox2
-expression of FA
Y10) in the presence of EGF and FGF 
S (d’). Bars in 









* P < 0.05
 in G144, 
down-regulated.




g, a’-c’ =50 µm, 





















4. Characteristics of the GSC lines
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6. Effects of cerulenin on sphere formation
M cerulenin. 
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